Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

As a result, healthcare professionals may prescribe another GLP-1 medication that works in a similar way to encourage weight loss. Although all Zepbound doses are currently available, individual ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

During your appointment, the healthcare professional reviews your medical history, discusses any health concerns, and assesses your weight loss goals to determine whether Zepbound suits you.

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Under medical supervision, GLP-1 agonists often lead to safe, sustainable weight loss, as noted in clinical reviews ... for a full list of side effects. Zepbound is a GLP-1 agonist containing ...